Aβ-Degrading Enzymes: Potential for Treatment of Alzheimer Disease
The DOI matches its Crossref record; 282 of the 287 references it cites were found in a registry or an index.
Abstract
There is increasing evidence that deficient clearance of β-amyloid (Aβ) contributes to its accumulation in late-onset Alzheimer disease (AD). Several Aβ-degrading enzymes, including neprilysin (NEP), insulin-degrading enzyme, and endothelin-converting enzyme reduce Aβ levels and protect against cognitive impairment in mouse models of AD. The activity of several Aβ-degrading enzymes rises with age and increases still further in AD, perhaps as a physiological response to minimize the buildup of Aβ. The age- and disease-related changes in expression of more recently recognized Aβ-degrading enzymes (e.g. NEP-2 and cathepsin B) remain to be investigated, and there is strong evidence that reduced NEP activity contributes to the development of cerebral amyloid angiopathy. Regardless of the role of Aβ-degrading enzymes in the development of AD, experimental data indicate that increasing the activity of these enzymes (NEP in particular) has therapeutic potential in AD, although targeting their delivery to the brain remains a major challenge. The most promising current approaches include the peripheral administration of agents that enhance the activity of Aβ-degrading enzymes and the direct intracerebral delivery of NEP by convection-enhanced delivery. In the longer term, genetic approaches to increasing the intracerebral expression of NEP or other Aβ-degrading enzymes may offer advantages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“through the production of various Aβ degrading enzymes, such as insulin-degrading enzyme (IDE), neprilysin (NEP), and MMP9, which may be secreted to degrade Aβ extracellularly [146–148]”
From Microglial dysfunction in brain aging and Alzheimer's disease (2014) · cites this paper as [146]
In the citing paper
“The Aβ degradation is ensured by some proteases, such as cathepsin and the insulin-degrading enzyme (IDE), which cleave the Aβ into smaller soluble fragments (Miners et al., 2011; Kurochkin et al., 2018).”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Miners et al., 2011
Citations
Cites
2 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedPulukuri, S. M. K., Estes, N., Patel, J., & Rao, J. S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2892 · Cited by 84 · cited 1×
“Several findings highlight the potential therapeutic use of valproate in AD (236): not only does it upregulate NEP, it also upregulates plasmin (237), and its safety and efficacy have been extensively documented in the treatment of epilepsy and psychosisYrelated behavioral problems (238).”
BackgroundRetractedAlternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189 · cited 1×
“Recent studies indicate that environmental stimuli largely determine whether microglia adopt a phagocytic ‘‘protective’’ response or a damaging ‘‘neurotoxic’’ response (205, 206) and that a proinflammatory response is associated with reduced microglial phagocytosis (207).”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396 · cited 1×
“Recent studies indicate that environmental stimuli largely determine whether microglia adopt a phagocytic ‘‘protective’’ response or a damaging ‘‘neurotoxic’’ response (205, 206) and that a proinflammatory response is associated with reduced microglial phagocytosis (207).”
BackgroundShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“Recent research suggests strongly that clearance rather than production of AA is impaired in late-onset sporadic AD (7).”
BackgroundJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022 · cited 9×
“The direct toxicity of not only AA1Y40 and AA1Y42 but also their degradation products, therefore, likely depends on how they combine to form assemblies in vivo because conversion from oligomers to protofibrils to fibrils is associated with a reduction in directly mediated damage to synapses and neurons (77).”
BackgroundInfluentialBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“Microglial uptake of AA, initiated by binding of antiAA antibody to Fc receptors (195, 196) or by Fc-independent mechanisms (197, 198), is thought to be a major route of plaque removal after AA immunization in mouse models of AD (196, 199) and in humans (200).”
BackgroundEffect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
Tang, M.-X., Jacobs, D., Stern, Y., Marder, K., Schofield, P., Gurland, B., Andrews, H., & Mayeux, R. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03356-9 · Cited by 1,647
Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability
Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201750200 · Cited by 1,452 · cited 1×
“AA exists in a dynamic equilibrium of soluble monomeric, oligomeric, protofibrillar, and fibrillar states (130).”
BackgroundHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Self-citationConvection-enhanced delivery of macromolecules in the brain.
Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., & Oldfield, E. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2076 · Cited by 1,415 · cited 1×
“Convection-enhanced delivery relies on a pressure gradient established at the tip of a very fine infusion catheter resulting in bulk flow of the infused fluid through the extracellular and perivascular spaces (259).”
BackgroundShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 2×
“The best characterized of these are illustrated in this diagram: enzymatic degradation within the brain parenchyma (17Y19); perivascular drainage of AA along basement membranes to cervical lymph nodes and into the cerebrospinal fluid (9, 10, 20); transport across vessel walls into the circulation, mediated by binding…”
BackgroundAmyloid, the presenilins and Alzheimer’s disease
Hardy, J. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01030-2 · Cited by 1,370
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“Levels of these receptors on microglia are significantly reduced in aged mice (194), suggesting that the ability of microglia to clear fAA may decline with age.”
BackgroundDirect brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Self-citationFarris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,286 · cited 1×
“Mice with inactivation ofNEP (46), NEP-2 (145), ECE-1, ECE-2 (92), or IDE genes (114, 146) all showed a moderate (1.”
BackgroundSimard, A. R., Soulet, D., Gowing, G., Julien, J.-P., & Rivest, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.022 · Cited by 1,265 · cited 1×
“CD36 and the receptor for advanced glycation end products [192]) and may restrict plaque formation by phagocytosis of AA (193).”
BackgroundStructural conversion of neurotoxic amyloid-β1–42 oligomers to fibrils
Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., Elliott, J. I., Van Nostrand, W. E., & Smith, S. O. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1799 · Cited by 1,111 · cited 1×
“The direct toxicity of not only AA1Y40 and AA1Y42 but also their degradation products, therefore, likely depends on how they combine to form assemblies in vivo because conversion from oligomers to protofibrils to fibrils is associated with a reduction in directly mediated damage to synapses and neurons (77).”
BackgroundLiu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035048 · Cited by 1,095
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · cited 1×
“This therapeutic strategy was applied to AD in a phase 1 clinical trial of ex vivo NGF gene therapy, in which autologous fibroblasts genetically modified to express NGF were neurosurgically implanted into the basal forebrains of 8 patients (255).”
MethodLammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiffer, R., Jasionowski, M., Haass, C., & Fahrenholz, F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3922 · Cited by 975
MEROPS: the peptidase database
Rawlings, N. D., Barrett, A. J., & Bateman, A. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp971 · Cited by 971
Metabolic Regulation of Brain Aβ by Neprilysin
Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C., Hama, E., Lee, H.-J., & Saido, T. C. (2001) · Science · doi:10.1126/science.1059946 · Cited by 961 · cited 2×
“Genetic ablation of the NEP gene (NEP) in hAPP mice confirmed the importance of NEP in preventing AA accumulation; endogenous AA increased, and clearance of exogenously administered AA was impaired, although not completely inhibited (46).”
BackgroundBuxbaum, J. D., Liu, K.-N., Luo, Y., Slack, J. L., Stocking, K. L., Peschon, J. J., Johnson, R. S., Castner, B. J., Cerretti, D. P., & Black, R. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.27765 · Cited by 934
Xu, D., Emoto, N., Giaid, A., Slaughter, C., Kaw, S., deWit, D., & Yanagisawa, M. (1994) · Cell · doi:10.1016/0092-8674(94)90425-1 · Cited by 921
Environmental Enrichment Reduces Aβ Levels and Amyloid Deposition in Transgenic Mice
Lazarov, O., Robinson, J., Tang, Y.-P., Hairston, I. S., Korade-Mirnics, Z., Lee, V. M.-Y., Hersh, L. B., Sapolsky, R. M., Mirnics, K., & Sisodia, S. S. (2005) · Cell · doi:10.1016/j.cell.2005.01.015 · Cited by 885
Insulin Degradation: Progress and Potential*
Duckworth, W. C., Bennett, R. G., & Hamel, F. G. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0349 · Cited by 871
Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 3×
“N, neprilysin (45Y49); E, endothelin-converting enzyme (49Y51); I, insulindegrading enzyme (47, 48, 52Y55); A, angiotensin-converting enzyme (56Y60); M2, matrix metalloproteinase 2 (61Y63); M9, matrix metalloproteinase 9 (64, 65); P, plasmin (28, 45, 51, 66, 67); C, CTSB (66); Mt1, membrane-type metalloproteinase 1 (6…”
BackgroundEstrogen Deficiency and Risk of Alzheimer's Disease in Women
Paganini-Hill, A., & Henderson, V. W. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117244 · Cited by 853 · cited 1×
“Postmenopausal estrogen deficiency is thought to be a risk factor for AD (239), and estrogen use in postmenopausal women was found to delay the onset and reduced the risk of J Neuropathol Exp Neurol Volume 70, Number 11, November 2011 AA-Degrading Enzymes in AD”
BackgroundInsulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
MEROPS: the peptidase database
Rawlings, N. D., & Barrett, A. J. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.325 · Cited by 793
Beta-amyloid precursor protein cleavage by a membrane-bound protease.
Sisodia, S. S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.6075 · Cited by 738
Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., Frosch, M. P., & Selkoe, D. J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00787-6 · Cited by 719
The role of microglia in amyloid clearance from the AD brain
Lee, C. Y. D., & Landreth, G. E. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0433-4 · Cited by 701 · cited 1×
“Soluble AA is sensitive to many proteases including NEP and IDE, although whether NEP and IDE are involved in the intracellular degradation of soluble AA has yet to be established (192).”
BackgroundPike, C. J., Walencewicz‐Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., & Cotman, C. W. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64010253.x · Cited by 699 · cited 2×
“AA peptide fragments AA25Y35 (140) and AA22Y35 (141) also have similar in vitro neurotoxicity and aggregation profiles to their full-length AA counterparts (142) and AA17Y20 and AA30Y35 peptide fragments, which themselves do not self-aggregate spontaneously promote the aggregation and neurotoxicity of full-length AA1Y…”
BackgroundWeller, R. O., Subash, M., Preston, S. D., Mazanti, I., & Carare, R. O. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00133.x · Cited by 681
Microglial response to amyloid plaques in APPsw transgenic mice.
Frautschy, S. A., Yang, F., Irrizarry, M., Hyman, B. T., Saido, T. C., Hsiao, K., & Cole, G. M. (1998) · Europe PMC (PubMed Central) · Cited by 679
Weller, R. O., Massey, A., Newman, T. A., Hutchings, M., Kuo, Y.-M., & Roher, A. E. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65616-7 · Cited by 679 · cited 1×
“The best characterized of these are illustrated in this diagram: enzymatic degradation within the brain parenchyma (17Y19); perivascular drainage of AA along basement membranes to cervical lymph nodes and into the cerebrospinal fluid (9, 10, 20); transport across vessel walls into the circulation, mediated by binding…”
BackgroundAmyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676 · cited 10×
“The direct toxicity of not only AA1Y40 and AA1Y42 but also their degradation products, therefore, likely depends on how they combine to form assemblies in vivo because conversion from oligomers to protofibrils to fibrils is associated with a reduction in directly mediated damage to synapses and neurons (77).”
BackgroundInfluentialCarare, R. O., Bernardes‐Silva, M., Newman, T. A., Page, A. M., Nicoll, J. A. R., Perry, V. H., & Weller, R. O. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00926.x · Cited by 665
Paresce, D. M., Ghosh, R. N., & Maxfield, F. R. (1996) · Neuron · doi:10.1016/s0896-6273(00)80187-7 · Cited by 663
Townsend, M., Shankar, G. M., Mehta, T., Walsh, D. M., & Selkoe, D. J. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2005.103754 · Cited by 619
Stem cells in human neurodegenerative disorders — time for clinical translation?
Lindvall, O., & Kokaia, Z. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40543 · Cited by 614 · cited 1×
“migration, and, in the case of nonautologous transplants, a lifelong requirement for immunosuppression (276, 277).”
BackgroundHuman amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice
Wyss-Coray, T., Lin, C., Yan, F., Yu, G.-Q., Rohde, M., McConlogue, L., Masliah, E., & Mucke, L. (2001) · Nature Medicine · doi:10.1038/87945 · Cited by 587 · cited 1×
“In vitro, the anti-inflammatory cytokines transforming growth factor A (TGF-A) and interleukin (IL)-4 increased microglial clearance of AA, including oligomeric AA (210, 211), and overexpression of TGF-A in hAPP mice resulted in a 70% reduction in parenchymal AA load (210).”
BackgroundDeane, R., Bell, R., Sagare, A., & Zlokovic, B. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601867 · Cited by 548 · cited 1×
“The best characterized of these are illustrated in this diagram: enzymatic degradation within the brain parenchyma (17Y19); perivascular drainage of AA along basement membranes to cervical lymph nodes and into the cerebrospinal fluid (9, 10, 20); transport across vessel walls into the circulation, mediated by binding…”
BackgroundChimon, S., Shaibat, M. A., Jones, C. R., Calero, D. C., Aizezi, B., & Ishii, Y. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1345 · Cited by 544 · cited 1×
“The cleavage products were also morphologically distinct, protease XIV cleavage products resembling oligomers (morphologically distinct from AA fibrils) (139), and those from >-chymotrypsin degradation having fibrillar characteristics.”
BackgroundHeneka, M. T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu-Ozimek, L., Terwel, D., Jardanhazi-Kurutz, D., Walter, J., Kirchhoff, F., Hanisch, U.-K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909586107 · Cited by 518 · cited 1×
“Heneka et al (209) reported that the addition of noradrenaline to cultures of microglia exposed to fibrillar AA1Y42 suppressed cytokine and chemokine production and promoted cell migration and phagocytosis of AA.”
BackgroundAmyloid-β oligomers: their production, toxicity and therapeutic inhibition
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Rowan, M. J., & Selkoe, D. J. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300552 · Cited by 507
A Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation
Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J., & Landreth, G. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02665.2003 · Cited by 501
Emoto, N., & Yanagisawa, M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.25.15262 · Cited by 499 · cited 7×
“For example, intracellular enzymes such as IDE (112, 137), which is predominantly cytosolic, and the lysosomal-endosomal proteases cathepsin B (CTSB) (138), ECE-1, and ECE-2 (92, 96) preferentially degrade soluble monomeric or oligomeric AA (138) that is internalized within neurons and microglia.”
BackgroundInfluentialVekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., Rosner, M. R., & Selkoe, D. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-05-01657.2000 · Cited by 495
Lymphatic drainage of the brain and the pathophysiology of neurological disease
Weller, R. O., Djuanda, E., Yow, H.-Y., & Carare, R. O. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0457-0 · Cited by 488
CD36 Mediates the Innate Host Response to β-Amyloid
El Khoury, J. B., Moore, K. J., Means, T. K., Leung, J., Terada, K., Toft, M., Freeman, M. W., & Luster, A. D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021546 · Cited by 483
Koenigsknecht-Talboo, J., & Landreth, G. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1808-05.2005 · Cited by 477 · cited 1×
“Recent studies indicate that environmental stimuli largely determine whether microglia adopt a phagocytic ‘‘protective’’ response or a damaging ‘‘neurotoxic’’ response (205, 206) and that a proinflammatory response is associated with reduced microglial phagocytosis (207).”
BackgroundAntiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease
Mueller-Steiner, S., Zhou, Y., Arai, H., Roberson, E. D., Sun, B., Chen, J., Wang, X., Yu, G., Esposito, L., Mucke, L., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.027 · Cited by 465 · cited 5×
“The levels of several other candidate AA-degrading proteases, namely, ECE-2 (31), MMP-2 and MMP-9 (64, 173), CTSB (32, 174, 175), and APEH (70), were reported to be elevated in AD; however, in other studies, the concentrations and activities of MMP-2, MMP-3, MMP-9, and plasmin were not increased (120, 124).”
BackgroundInfluentialThe neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function
Turner, A. J., Isaac, R. E., & Coates, D. (2001) · BioEssays · doi:10.1002/1521-1878(200103)23:3<261::aid-bies1036>3.0.co;2-k · Cited by 452
Microglial Phagocytosis of Fibrillar β-Amyloid through a β1Integrin-Dependent Mechanism
Koenigsknecht, J., & Landreth, G. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2557-04.2004 · Cited by 446
Microglia Mediate the Clearance of Soluble Aβ through Fluid Phase Macropinocytosis
Mandrekar, S., Jiang, Q., Lee, C. Y. D., Koenigsknecht-Talboo, J., Holtzman, D. M., & Landreth, G. E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5572-08.2009 · Cited by 415 · cited 1×
“In contrast, uptake and clearance of soluble AA is rapid and involves macropinocytosis and rapid delivery to lysosomes (223).”
BackgroundBard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., Guido, T., Hoenow, K., Hu, K., Johnson-Wood, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436286100 · Cited by 411 · cited 1×
“Microglial uptake of AA, initiated by binding of antiAA antibody to Fc receptors (195, 196) or by Fc-independent mechanisms (197, 198), is thought to be a major route of plaque removal after AA immunization in mouse models of AD (196, 199) and in humans (200).”
BackgroundCalhoun, M. E., Burgermeister, P., Phinney, A. L., Stalder, M., Tolnay, M., Wiederhold, K.-H., Abramowski, D., Sturchler-Pierrat, C., Sommer, B., Staufenbiel, M., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14088 · Cited by 410
Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX
Turner, A. J., & Tanzawa, K. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.5.9141502 · Cited by 402
Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice
Marr, R. A., Rockenstein, E., Mukherjee, A., Kindy, M. S., Hersh, L. B., Gage, F. H., Verma, I. M., & Masliah, E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-01992.2003 · Cited by 392 · cited 2×
“Unilateral injection of lentivirus or adenovirus encoding human NEP into the hippocampus of hAPP mice reduced AA load and significantly improved performance in memory tasks (159, 160).”
BackgroundMiners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G., & Love, S. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00132.x · Cited by 381 · cited 1×
“Increases in AA-degrading protease activity in AD are, therefore, more likely to be a protective response to the accumulation of AA (18).”
BackgroundSelf-citationMatrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism
Yin, K.-J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., Bateman, R., Song, H., Hsu, F.-F., Turk, J., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2085-06.2006 · Cited by 381 · cited 1×
“Further support comes from the rise in IDE level (29), tissue plasminogen activator and urokinase plasminogen activator activity (28), and MMP-2 and -9 activity (27) in aged hAPP mice and the dosedependent induction of neuronal NEP in hAPP mice given intracerebral injections of synthetic fibrillar AA (177, 178).”
BackgroundMicroglia and inflammatory mechanisms in the clearance of amyloid β peptide
Rogers, J., Strohmeyer, R., Kovelowski, C. J., & Li, R. (2002) · Glia · doi:10.1002/glia.10153 · Cited by 381 · cited 1×
“The best characterized of these are illustrated in this diagram: enzymatic degradation within the brain parenchyma (17Y19); perivascular drainage of AA along basement membranes to cervical lymph nodes and into the cerebrospinal fluid (9, 10, 20); transport across vessel walls into the circulation, mediated by binding…”
Backgroundβ‐Amyloid efflux mediated by p‐glycoprotein
Lam, F. C., Liu, R., Lu, P., Shapiro, A. B., Renoir, J., Sharom, F. J., & Reiner, P. B. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00113.x · Cited by 380
Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602440200 · Cited by 380 · cited 4×
“The levels of several other candidate AA-degrading proteases, namely, ECE-2 (31), MMP-2 and MMP-9 (64, 173), CTSB (32, 174, 175), and APEH (70), were reported to be elevated in AD; however, in other studies, the concentrations and activities of MMP-2, MMP-3, MMP-9, and plasmin were not increased (120, 124).”
BackgroundInfluentialClearance of amyloid-β by circulating lipoprotein receptors
Sagare, A., Deane, R., Bell, R. D., Johnson, B., Hamm, K., Pendu, R., Marky, A., Lenting, P. J., Wu, Z., Zarcone, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1635 · Cited by 373 · cited 6×
“These include drainage along perivascular basement membranes, possibly to cervical lymph nodes and into the cerebrospinal fluid (CSF) (8Y10); transport across vessel walls into the circulation, mediated by low-density lipoprotein receptor-related protein 1 (11) or the P-glycoprotein (PgP/MDR1/ABCB1) efflux pump (12Y14…”
BackgroundInfluentialThe presenilins and Alzheimer's disease
Hutton, M. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.10.1639 · Cited by 368
Zhao, J., Fu, Y., Yasvoina, M., Shao, P., Hitt, B., O'Connor, T., Logan, S., Maus, E., Citron, M., Berry, R., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4396-06.2007 · Cited by 365 · cited 1×
“To date, there is little evidence to suggest that an increase in the overall production of AA is responsible for the development of sporadic AD in most cases (6).”
BackgroundHawkes, C. A., Härtig, W., Kacza, J., Schliebs, R., Weller, R. O., Nicoll, J. A., & Carare, R. O. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0801-7 · Cited by 364 · cited 15×
“Our findings provide strong evidence that NEP protects CVSMCs from AA toxicity and protects cerebral blood vessels from the development and complications of CAA.”
BackgroundInfluentialSomatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation
Saito, T., Iwata, N., Tsubuki, S., Takaki, Y., Takano, J., Huang, S.-M., Suemoto, T., Higuchi, M., & Saido, T. C. (2005) · Nature Medicine · doi:10.1038/nm1206 · Cited by 361 · cited 6×
“The neuropeptide SST upregulates NEP activity in vitro (157) through activation of the SST receptors, SSTR2 and SSTR4, suggesting that AA levels might be controlled by SST receptor agonists (226).”
BackgroundInfluentialHu, J., Igarashi, A., Kamata, M., & Nakagawa, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104068200 · Cited by 360 · cited 1×
“The products of AA proteolytic cleavage by ACE (cleavage between Asp(7)-Ser(8)) are less neurotoxic, less likely to aggregate, and are more easily cleared than fulllength AA (56).”
BackgroundYasojima, K., Akiyama, H., McGeer, E. G., & McGeer, P. L. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01675-x · Cited by 356
Pardossi-Piquard, R., Petit, A., Kawarai, T., Sunyach, C., Alves da Costa, C., Vincent, B., Ring, S., D’Adamio, L., Shen, J., Müller, U., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.04.008 · Cited by 348
Vogelgesang, S., Cascorbi, I., Schroeder, E., Pahnke, J., Kroemer, H. K., Siegmund, W., Kunert-Keil, C., Walker, L. C., & Warzok, R. W. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00005 · Cited by 345
Insulin Degradation: Progress and Potential
Duckworth, W. C. (1998) · Endocrine Reviews · doi:10.1210/er.19.5.608 · Cited by 344
Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme
Eckman, E. A., Reed, D. K., & Eckman, C. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007579200 · Cited by 342 · cited 1×
“N, neprilysin (45Y49); E, endothelin-converting enzyme (49Y51); I, insulindegrading enzyme (47, 48, 52Y55); A, angiotensin-converting enzyme (56Y60); M2, matrix metalloproteinase 2 (61Y63); M9, matrix metalloproteinase 9 (64, 65); P, plasmin (28, 45, 51, 66, 67); C, CTSB (66); Mt1, membrane-type metalloproteinase 1 (6…”
Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion
Lieberman, D. M., Laske, D. W., Morrison, P. F., Bankiewicz, K. S., & Oldfield, E. H. (1995) · Journal of Neurosurgery · doi:10.3171/jns.1995.82.6.1021 · Cited by 341
Kurochkin, I. V., & Goto, S. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00387-4 · Cited by 340
Hemming, M. L., & Selkoe, D. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508460200 · Cited by 332
Backstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331
Cook, D. G., Leverenz, J. B., McMillan, P. J., Kulstad, J. J., Ericksen, S., Roth, R. A., Schellenberg, G. D., Jin, L.-W., Kovacina, K. S., & Craft, S. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63822-9 · Cited by 331
Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy
Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-07873.2002 · Cited by 323 · cited 1×
“Microglial uptake of AA, initiated by binding of antiAA antibody to Fc receptors (195, 196) or by Fc-independent mechanisms (197, 198), is thought to be a major route of plaque removal after AA immunization in mouse models of AD (196, 199) and in humans (200).”
BackgroundShirotani, K., Tsubuki, S., Iwata, N., Takaki, Y., Harigaya, W., Maruyama, K., Kiryu-Seo, S., Kiyama, H., Iwata, H., Tomita, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008511200 · Cited by 311 · cited 1×
“Neprilysin, the prototypic AA-degrading metalloendopeptidase, has been shown to be the most efficient of a range of thiorphan- and phosphoramidon-sensitive endopeptidases in degrading AA in vitro (144).”
BackgroundThe Plasmin System Is Induced by and Degrades Amyloid-β Aggregates
Tucker, H. M., Kihiko, M., Caldwell, J. N., Wright, S., Kawarabayashi, T., Price, D., Walker, D., Scheff, S., McGillis, J. P., Rydel, R. E., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-03937.2000 · Cited by 309 · cited 2×
“N, neprilysin (45Y49); E, endothelin-converting enzyme (49Y51); I, insulindegrading enzyme (47, 48, 52Y55); A, angiotensin-converting enzyme (56Y60); M2, matrix metalloproteinase 2 (61Y63); M9, matrix metalloproteinase 9 (64, 65); P, plasmin (28, 45, 51, 66, 67); C, CTSB (66); Mt1, membrane-type metalloproteinase 1 (6…”
BackgroundWeller, R. O., Boche, D., & Nicoll, J. A. R. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0498-z · Cited by 297 · cited 15×
“Our findings provide strong evidence that NEP protects CVSMCs from AA toxicity and protects cerebral blood vessels from the development and complications of CAA.”
BackgroundInfluentialAmyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo
Miller, B. C., Eckman, E. A., Sambamurti, K., Dobbs, N., Chow, K. M., Eckman, C. B., Hersh, L. B., & Thiele, D. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031520100 · Cited by 294 · cited 1×
“Mice with inactivation ofNEP (46), NEP-2 (145), ECE-1, ECE-2 (92), or IDE genes (114, 146) all showed a moderate (1.”
BackgroundCerebral Amyloid Angiopathies: A Pathologic, Biochemical, and Genetic View
Revesz, T., Ghiso, J., Lashley, T., Plant, G., Rostagno, A., Frangione, B., & Holton, J. L. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.9.885 · Cited by 288 · cited 1×
“The most common form of CAA is caused by the accumulation of AA in the walls of leptomeningeal and cerebrocortical blood vessels, particularly arterioles (180, 181).”
BackgroundDegradation of myofibrillar proteins by cathepsins B and D
Schwartz, W. N., & Bird, J. W. C. (1977) · Biochemical Journal · doi:10.1042/bj1670811 · Cited by 286
Glial cell line–derived neurotrophic factor induces neuronal sprouting in human brain
Love, S., Plaha, P., Patel, N. K., Hotton, G. R., Brooks, D. J., & Gill, S. S. (2005) · Nature Medicine · doi:10.1038/nm0705-703 · Cited by 285
Self-citationKOIKE, H., Tomioka, S., Sorimachi, H., Saido, T. C., Maruyama, K., Okuyama, A., Fujisawa‐Sehara, A., Ohno, S., Suzuki, K., & Ishiura, S. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3430371 · Cited by 278
Slow Degradation of Aggregates of the Alzheimer's Disease Amyloid β-Protein by Microglial Cells
Paresce, D. M., Chung, H., & Maxfield, F. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.46.29390 · Cited by 271 · cited 1×
“Because fAA has shown considerable resistance to proteolytic cleavage, the extent to which internalized fAA is efficiently degraded remains unclear (216, 217).”
BackgroundActivation of Microglia Acidifies Lysosomes and Leads to Degradation of Alzheimer Amyloid Fibrils
Majumdar, A., Cruz, D., Asamoah, N., Buxbaum, A., Sohar, I., Lobel, P., & Maxfield, F. R. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-10-0975 · Cited by 271 · cited 1×
“Degradation of internalized AA in primary mouse microglia was mediated by acidification of lysosomes (to pH È5Y6) after activation by the proinflammatory mediators, macrophage-stimulating colony factor and IL-6 (218).”
BackgroundAβ Species Removal After Aβ 42 Immunization
Nicoll, J. A. R., Barton, E., Boche, D., Neal, J. W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., et al. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240466.10758.ce · Cited by 265
β‐Amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?
Carson, J. A., & Turner, A. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00855.x · Cited by 261 · cited 1×
“These data are summarized from Carson and Turner (74), Wang et al (75), and Eckman and Eckman (76).”
MethodIwata, N., Mizukami, H., Shirotani, K., Takaki, Y., Muramatsu, S.-I., Lu, B., Gerard, N. P., Gerard, C., Ozawa, K., & Saido, T. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4792-03.2004 · Cited by 257 · cited 2×
“Unilateral injection of lentivirus or adenovirus encoding human NEP into the hippocampus of hAPP mice reduced AA load and significantly improved performance in memory tasks (159, 160).”
BackgroundPreston, S. D., Steart, P. V., Wilkinson, A., Nicoll, J. A. R., & Weller, R. O. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00424.x · Cited by 239 · cited 1×
“The best characterized of these are illustrated in this diagram: enzymatic degradation within the brain parenchyma (17Y19); perivascular drainage of AA along basement membranes to cervical lymph nodes and into the cerebrospinal fluid (9, 10, 20); transport across vessel walls into the circulation, mediated by binding…”
BackgroundRogers, J., & Lue, L.-F. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00040-7 · Cited by 236 · cited 2×
“The best characterized of these are illustrated in this diagram: enzymatic degradation within the brain parenchyma (17Y19); perivascular drainage of AA along basement membranes to cervical lymph nodes and into the cerebrospinal fluid (9, 10, 20); transport across vessel walls into the circulation, mediated by binding…”
BackgroundA New Pathogenic Mutation in the APP Gene (I716V) Increases the Relative Proportion of A 42(43)
Eckman, C. B., Mehta, N. D., Crook, R., Perez-tur, J., Prihar, G., Pfeiffer, E., Graff-Radford, N., Hinder, P., Yager, D., Zenk, B., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.12.2087 · Cited by 236
Escribano, L., Simón, A.-M., Gimeno, E., Cuadrado-Tejedor, M., López de Maturana, R., García-Osta, A., Ricobaraza, A., Pérez-Mediavilla, A., Del Río, J., & Frechilla, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.32 · Cited by 235 · cited 1×
“Administration of rosiglitazone (a peroxisome proliferatoractivated receptor agonist) facilitates AA removal in hAPP mice by switching on the phagocytic phenotype of microglia, a process that is mediated by the suppression of proinflammatory mediators (208).”
BackgroundWilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03745.2003 · Cited by 232 · cited 1×
“Microglial uptake of AA, initiated by binding of antiAA antibody to Fc receptors (195, 196) or by Fc-independent mechanisms (197, 198), is thought to be a major route of plaque removal after AA immunization in mouse models of AD (196, 199) and in humans (200).”
BackgroundKanemitsu, H., Tomiyama, T., & Mori, H. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00898-x · Cited by 228
Kuhnke, D., Jedlitschky, G., Grube, M., Krohn, M., Jucker, M., Mosyagin, I., Cascorbi, I., Walker, L. C., Kroemer, H. K., Warzok, R. W., et al. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00075.x · Cited by 226
Van Dorpe, J., Smeijers, L., Dewachter, I., Nuyens, D., Spittaels, K., Van den Haute, C., Mercken, M., Moechars, D., Laenen, I., Kuiperi, C., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64644-5 · Cited by 225
Metabolism of amyloid-β peptide and Alzheimer's disease
Iwata, N., Higuchi, M., & Saido, T. C. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.03.010 · Cited by 220
Alzheimer's Disease β-Amyloid Peptide Is Increased in Mice Deficient in Endothelin-converting Enzyme
Eckman, E. A., Watson, M., Marlow, L., Sambamurti, K., & Eckman, C. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200642200 · Cited by 218 · cited 7×
“For example, intracellular enzymes such as IDE (112, 137), which is predominantly cytosolic, and the lysosomal-endosomal proteases cathepsin B (CTSB) (138), ECE-1, and ECE-2 (92, 96) preferentially degrade soluble monomeric or oligomeric AA (138) that is internalized within neurons and microglia.”
BackgroundInfluentialTamboli, I. Y., Barth, E., Christian, L., Siepmann, M., Kumar, S., Singh, S., Tolksdorf, K., Heneka, M. T., Lütjohann, D., Wunderlich, P., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149468 · Cited by 218 · cited 2×
“Tamboli et al (224) reported that statins promote microglial removal of AA by inducing the release of exosomal IDE.”
BackgroundSavaskan, E., Hock, C., Olivieri, G., Bruttel, S., Rosenberg, C., Hulette, C., & Müller-Spahn, F. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00259-1 · Cited by 217 · cited 1×
“The activity of ACE was similarly increased in AD (33, 99, 100).”
BackgroundXia, W., Yang, T., Shankar, G., Smith, I. M., Shen, Y., Walsh, D. M., & Selkoe, D. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.565 · Cited by 216
Ledesma, M. D., Da Silva, J. S., Crassaerts, K., Delacourte, A., De Strooper, B., & Dotti, C. G. (2000) · EMBO reports · doi:10.1093/embo-reports/kvd107 · Cited by 216
The microglial phagocytic role with specific plaque types in the Alzheimer disease brain
D’Andrea, M. R., Cole, G. M., & Ard, M. D. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.026 · Cited by 215
Chung, H., Brazil, M. I., Soe, T. T., & Maxfield, F. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32301 · Cited by 212 · cited 1×
“Because fAA has shown considerable resistance to proteolytic cleavage, the extent to which internalized fAA is efficiently degraded remains unclear (216, 217).”
BackgroundHowell, S., Nalbantoglu, J., & Crine, P. (1995) · Peptides · doi:10.1016/0196-9781(95)00021-b · Cited by 204
Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations
SCHWEIZER, A., VALDENAIRE, O., NELBÖCK, P., DEUSCHLE, U., DUMAS MILNE EDWARDS, J.-B., STUMPF, J. G., & LÖFFLER, B.-M. (1997) · Biochemical Journal · doi:10.1042/bj3280871 · Cited by 203
Eckman, C. B., & Eckman, E. A. (2005) · Biochemical Society Transactions · doi:10.1042/bst20051101 · Cited by 200 · cited 1×
“These data are summarized from Carson and Turner (74), Wang et al (75), and Eckman and Eckman (76).”
MethodSporadic and Familial Cerebral Amyloid Angiopathies
Revesz, T., Holton, J. L., Lashley, T., Plant, G., Rostagno, A., Ghiso, J., & Frangione, B. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00449.x · Cited by 199 · cited 1×
“The most common form of CAA is caused by the accumulation of AA in the walls of leptomeningeal and cerebrocortical blood vessels, particularly arterioles (180, 181).”
BackgroundAmyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease
Hyman, B. T. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.70 · Cited by 197 · cited 1×
“Strategies directed at the removal of AA in advanced disease, particularly AA immunotherapy in human clinical trials, have resulted in the clearance of AA plaques without improvement in cognitive performance (278), suggesting that downstream pathogenic processes eventually become independent of the continued accumulat…”
BackgroundEckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196 · cited 1×
“Genetic knockout of plasmin, urokinase plasminogen activator, or tissue plasminogen activator, other candidate proteases that cleave AA in vitro, did not result in alterations in endogenous AA (148), nor did the absence of ACE alter steadystate levels of AA (149, 150).”
BackgroundNeprilysin: An Enzyme Candidate to Slow the Progression of Alzheimer's Disease
El-Amouri, S. S., Zhu, H., Yu, J., Marr, R., Verma, I. M., & Kindy, M. S. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070620 · Cited by 187 · cited 5×
“Although it remains unproven that a decline in AAdegrading enzyme activity contributes to the accumulation of AA in AD (25, 26, 171), it is clear that overexpression of AA-degrading enzymes, neprilysin in particular, can reduce amyloid deposition and ameliorate cognitive decline in AD animal models (155, 161, 162).”
BackgroundInfluentialProspects of stem cell therapy for replacing dopamine neurons in Parkinson's disease
Lindvall, O., & Kokaia, Z. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.03.001 · Cited by 187 · cited 1×
“migration, and, in the case of nonautologous transplants, a lifelong requirement for immunosuppression (276, 277).”
BackgroundHuman Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways
Wisner, A., Dufour, E., Messaoudi, M., Nejdi, A., Marcel, A., Ungeheuer, M.-N., & Rougeot, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605865103 · Cited by 186 · cited 1×
“Overexpression of NEP by neurons in a Drosophila model of AD decreased AA1Y42 accumulation and neuronal loss but also led to an age-dependent axonal degeneration and shortened the lifespan of the flies (250), probably caused by the effects on physiological neuropeptide substrates of NEP, including enkephalin, substanc…”
Backgroundβ‐Amyloid Degradation and Alzheimer′s Disease
Wang, D.-S., Dickson, D. W., & Malter, J. S. (2006) · BioMed Research International · doi:10.1155/jbb/2006/58406 · Cited by 185 · cited 1×
“These data are summarized from Carson and Turner (74), Wang et al (75), and Eckman and Eckman (76).”
MethodDeane, R., Sagare, A., & Zlokovic, B. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784705487 · Cited by 183 · cited 1×
“The best characterized of these are illustrated in this diagram: enzymatic degradation within the brain parenchyma (17Y19); perivascular drainage of AA along basement membranes to cervical lymph nodes and into the cerebrospinal fluid (9, 10, 20); transport across vessel walls into the circulation, mediated by binding…”
BackgroundHuang, S.-M., Mouri, A., Kokubo, H., Nakajima, R., Suemoto, T., Higuchi, M., Staufenbiel, M., Noda, Y., Yamaguchi, H., Nabeshima, T., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601372200 · Cited by 181 · cited 2×
“Other authors have reported that NEP is able to cleave dimers, trimers, tetramers, and other oligomeric species of AA (82, 83).”
BackgroundPopulation studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review
Keage, H. A., Carare, R. O., Friedland, R. P., Ince, P. G., Love, S., Nicoll, J. A., Wharton, S. B., Weller, R. O., & Brayne, C. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-3 · Cited by 181 · cited 1×
“The prevalence and severity of sporadic CAA increases with age and in AD (44, 182, 183).”
BackgroundSelf-citationLoss of Neprilysin Function Promotes Amyloid Plaque Formation and Causes Cerebral Amyloid Angiopathy
Farris, W., Schütz, S. G., Cirrito, J. R., Shankar, G. M., Sun, X., George, A., Leissring, M. A., Walsh, D. M., Qiu, W. Q., Holtzman, D. M., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070105 · Cited by 177 · cited 16×
“Moreover, the severity of CAA was greater in NEP than NEP mice (152).”
BackgroundInfluentialBelyaev, N. D., Nalivaeva, N. N., Makova, N. Z., & Turner, A. J. (2009) · EMBO reports · doi:10.1038/embor.2008.222 · Cited by 176 · cited 2×
“Transcriptional regulation of NEP is regulated by histone acetylation; histone deacetylase inhibitors valproate and trichostatin A raised NEP enzyme activity in SH-SY-5Y cells, which normally express NEP only at low levels (234).”
BackgroundValdenaire, O., Lepailleur‐Enouf, D., Egidy, G., Thouard, A., Barret, A., Vranckx, R., Tougard, C., & Michel, J. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00602.x · Cited by 170
Wang, S., Wang, R., Chen, L., Bennett, D. A., Dickson, D. W., & Wang, D. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06899.x · Cited by 170 · cited 1×
“Furthermore, the reduction in both NEP and IDE in AD was more pronounced in brain tissue from APOE ?4-positive patients (80, 106, 166, 167), whereas Hellstrom-Lindahl et al (168) reported decreased NEP protein (measured by immunoblot analysis) in AD and with age.”
BackgroundGene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia
Walker, D. G., Lue, L. F., & Beach, T. G. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00306-2 · Cited by 170
Biogenesis and metabolism of Alzheimer’s disease Aβ amyloid peptides
Evin, G., & Weidemann, A. (2002) · Peptides · doi:10.1016/s0196-9781(02)00063-3 · Cited by 170
Degradation of Amylin by Insulin-degrading Enzyme
Bennett, R. G., Duckworth, W. C., & Hamel, F. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006170200 · Cited by 170
Residues 17–20 and 30–35 of beta‐amyloid play critical roles in aggregation
Liu, R., McAllister, C., Lyubchenko, Y., & Sierks, M. R. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.10859 · Cited by 167 · cited 10×
“The direct toxicity of not only AA1Y40 and AA1Y42 but also their degradation products, therefore, likely depends on how they combine to form assemblies in vivo because conversion from oligomers to protofibrils to fibrils is associated with a reduction in directly mediated damage to synapses and neurons (77).”
BackgroundInfluentialMiners, J. S., Ashby, E., Van Helmond, Z., Chalmers, K. A., Palmer, L. E., Love, S., & Kehoe, P. G. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00885.x · Cited by 166 · cited 1×
“The activity of ACE was similarly increased in AD (33, 99, 100).”
BackgroundSelf-citationPatel, S. J., Shapiro, W. R., Laske, D. W., Jensen, R. L., Asher, A. L., Wessels, B. W., Carpenter, S. P., & Shan, J. S. (2005) · Neurosurgery · doi:10.1227/01.neu.0000159649.71890.30 · Cited by 166
Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/-Knock-Out Mice
Das, P., Howard, V., Loosbrock, N., Dickson, D., Murphy, M. P., & Golde, T. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-24-08532.2003 · Cited by 165
Hellström-Lindahl, E., Ravid, R., & Nordberg, A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.10.010 · Cited by 165 · cited 3×
“4-positive patients (80, 106, 166, 167), whereas Hellstrom-Lindahl et al (168) reported decreased NEP protein (measured by immunoblot analysis) in AD and with age.”
BackgroundIncreased Matrix Metalloproteinase 9 Activity in Mild Cognitive Impairment
Bruno, M. A., Mufson, E. J., Wuu, J., & Cuello, A. C. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181c22569 · Cited by 162 · cited 3×
“The levels of several other candidate AA-degrading proteases, namely, ECE-2 (31), MMP-2 and MMP-9 (64, 173), CTSB (32, 174, 175), and APEH (70), were reported to be elevated in AD; however, in other studies, the concentrations and activities of MMP-2, MMP-3, MMP-9, and plasmin were not increased (120, 124).”
BackgroundFukami, S., Watanabe, K., Iwata, N., Haraoka, J., Lu, B., Gerard, N. P., Gerard, C., Fraser, P., Westaway, D., George-Hyslop, P. S., et al. (2002) · Neuroscience Research · doi:10.1016/s0168-0102(02)00015-9 · Cited by 157
Lowenstein, P., Mandel, R., Xiong, W.-D., Kroeger, K., & Castro, M. (2007) · Current Gene Therapy · doi:10.2174/156652307782151498 · Cited by 157 · cited 1×
“However, this approach is associated with systemic and local immune responses that can neutralize the therapeutic effects (249).”
BackgroundAnterior pituitary hormones, stress, and immune system homeostasis
Dorshkind, K., & Horseman, N. D. (2001) · BioEssays · doi:10.1002/1521-1878(200103)23:3<288::aid-bies1039>3.0.co;2-p · Cited by 156
Miners, J. S., Van Helmond, Z., Chalmers, K., Wilcock, G., Love, S., & Kehoe, P. G. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000240463.87886.9a · Cited by 154 · cited 19×
“Our findings provide strong evidence that NEP protects CVSMCs from AA toxicity and protects cerebral blood vessels from the development and complications of CAA.”
BackgroundInfluentialSelf-citationTomanin, R., & Scarpa, M. (2004) · Current Gene Therapy · doi:10.2174/1566523043346011 · Cited by 152
Bulloj, A., Leal, M. C., Xu, H., Castaño, E. M., & Morelli, L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1206 · Cited by 149 · cited 1×
“Microglia express IDE, which gets incorporated within exosomes, and these are then secreted (111).”
BackgroundExocytosis of active cathepsin B: Enzyme activity at pH 7.0, inhibition and molecular mass
Linebaugh, B. E., Sameni, M., Day, N. A., Sloane, B. F., & Keppler, D. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00582.x · Cited by 148
Skidgel, R. A., & Erdös, E. G. (2004) · Peptides · doi:10.1016/j.peptides.2003.12.010 · Cited by 148
Hydrolysis of Peptide Hormones by Endothelin-converting Enzyme-1
Johnson, G. D., Stevenson, T., & Ahn, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.7.4053 · Cited by 146
Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease
Weller, R. O., Preston, S. D., Subash, M., & Carare, R. O. (2009) · Alzheimer's Research & Therapy · doi:10.1186/alzrt6 · Cited by 144 · cited 1×
“The AA accumulates initially in the basement membranes but eventually causes the death of cerebrovascular smooth muscle cells (CVSMCs), replacement of the tunica media, and, particularly in larger leptomeningeal vessels, patchy replacement of the adventitia (8).”
BackgroundIL-4-Induced Selective Clearance of Oligomeric β-Amyloid Peptide1–42 by Rat Primary Type 2 Microglia
Shimizu, E., Kawahara, K., Kajizono, M., Sawada, M., & Nakayama, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6503 · Cited by 143 · cited 2×
“Both NEP and IDE expression were increased in rat microglia by treatment with IL-4 (211).”
BackgroundProteolysis of Aβ Peptide from Alzheimer Disease Brain by Gelatinase A
Roher, A. E., Kasunic, T. C., Woods, A. S., Cotter, R. J., Ball, M. J., & Fridman, R. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2872 · Cited by 136
Oba, R., Igarashi, A., Kamata, M., Nagata, K., Takano, S., & Nakagawa, H. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03912.x · Cited by 133
Mukherjee, A., Song, E.-S., Kihiko-Ehmann, M., Goodman, J. P., Pyrek, J. S., Estus, S., & Hersh, L. B. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-23-08745.2000 · Cited by 129 · cited 1×
“Insulin-degrading enzymeYmediated cleavage of AA1Y40 and AA1Y42 eliminates the toxic effects of these proteins on rat cortical cells (52) and CTSB cleavage of AA1Y42 FIGURE 1.”
BackgroundHemming, M. L., Selkoe, D. J., & Farris, W. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.01.004 · Cited by 128 · cited 1×
“Genetic knockout of plasmin, urokinase plasminogen activator, or tissue plasminogen activator, other candidate proteases that cleave AA in vitro, did not result in alterations in endogenous AA (148), nor did the absence of ACE alter steadystate levels of AA (149, 150).”
BackgroundKong, Y., Ruan, L., Qian, L., Liu, X., & Le, Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2985-10.2010 · Cited by 127 · cited 1×
“Norepinephrine (noradrenaline), which suppresses neuroinflammation (see previous paragraphs), was also found to promote uptake of AA by induction of mouse AA formyl peptide receptor but also to clear AA through production of IDE (225).”
BackgroundValproate: a simple chemical with so much to offer
Peterson, G. M., & Naunton, M. (2005) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2005.00671.x · Cited by 127 · cited 1×
“Several findings highlight the potential therapeutic use of valproate in AD (236): not only does it upregulate NEP, it also upregulates plasmin (237), and its safety and efficacy have been extensively documented in the treatment of epilepsy and psychosisYrelated behavioral problems (238).”
BackgroundMeilandt, W. J., Cisse, M., Ho, K., Wu, T., Esposito, L. A., Scearce-Levie, K., Cheng, I. H., Yu, G.-Q., & Mucke, L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2984-08.2009 · Cited by 126 · cited 1×
“Meilandt et al (156) did not show improvement in spatial learning and memory in NEP/ hAPP double transgenic mice (È11-fold increase in NEP) despite a 50% reduction in soluble AA and prevention in plaque formation; the authors suggested that the lack of improvement reflected an inability of NEP to cleave trimers and AA…”
BackgroundGan, L., Ye, S., Chu, A., Anton, K., Yi, S., Vincent, V. A., von Schack, D., Chin, D., Murray, J., Lohr, S., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306183200 · Cited by 126 · cited 5×
“For example, intracellular enzymes such as IDE (112, 137), which is predominantly cytosolic, and the lysosomal-endosomal proteases cathepsin B (CTSB) (138), ECE-1, and ECE-2 (92, 96) preferentially degrade soluble monomeric or oligomeric AA (138) that is internalized within neurons and microglia.”
BackgroundInfluentialLebson, L., Nash, K., Kamath, S., Herber, D., Carty, N., Lee, D. C., Li, Q., Szekeres, K., Jinwal, U., Koren, J., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.0329-10.2010 · Cited by 124 · cited 1×
“Lebson et al (247) used peripheral bone marrow cells (CD11b+ monocytes) to deliver NEP in the brain.”
BackgroundCarpentier, M., Robitaille, Y., DesGroseillers, L., Boileau, G., & Marcinkiewicz, M. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.10.849 · Cited by 120 · cited 1×
“Neprilysin is expressed by CVSMCs within larger arterioles in the cerebral cortex and leptomeninges (80, 81), and ECE-1 (89) and IDE (116, 117) are expressed by endothelial cells.”
BackgroundHemming, M. L., Patterson, M., Reske-Nielsen, C., Lin, L., Isacson, O., & Selkoe, D. J. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040262 · Cited by 119 · cited 1×
“Hippocampal transplantation of fibroblasts transfected with complementary DNA encoding soluble NEP reduced plaque burden in hAPP mice (253).”
BackgroundMechanism mediating oligomeric Aβ clearance by naïve primary microglia
Yang, C.-N., Shiao, Y.-J., Shie, F.-S., Guo, B.-S., Chen, P.-H., Cho, C.-Y., Chen, Y.-J., Huang, F.-L., & Tsay, H.-J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.01.005 · Cited by 117 · cited 5×
“For example, intracellular enzymes such as IDE (112, 137), which is predominantly cytosolic, and the lysosomal-endosomal proteases cathepsin B (CTSB) (138), ECE-1, and ECE-2 (92, 96) preferentially degrade soluble monomeric or oligomeric AA (138) that is internalized within neurons and microglia.”
BackgroundInfluentialLee, J., Yin, K., Hsin, I., Chen, S., Fryer, J. D., Holtzman, D. M., Hsu, C. Y., & Xu, J. (2003) · Annals of Neurology · doi:10.1002/ana.10671 · Cited by 115
WELLER, R. O., MASSEY, A., KUO, Y., & ROHER, A. E. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06356.x · Cited by 115 · cited 1×
“The best characterized of these are illustrated in this diagram: enzymatic degradation within the brain parenchyma (17Y19); perivascular drainage of AA along basement membranes to cervical lymph nodes and into the cerebrospinal fluid (9, 10, 20); transport across vessel walls into the circulation, mediated by binding…”
BackgroundBernstein, H., Ansorge, S., Riederer, P. F., Reiser, M., Frölich, L., & Bogerts, B. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00135-4 · Cited by 115
Kroll, R. A., Pagel, M. A., Muldoon, L. L., Roman-Goldstein, S., & Neuwelt, E. A. (1996) · Neurosurgery · doi:10.1097/00006123-199604000-00024 · Cited by 114
Endothelin-Converting Enzyme-2 Is Increased in Alzheimer’s Disease and Up-Regulated by Aβ
Palmer, J. C., Baig, S., Kehoe, P. G., & Love, S. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081054 · Cited by 113 · cited 6×
“For example, intracellular enzymes such as IDE (112, 137), which is predominantly cytosolic, and the lysosomal-endosomal proteases cathepsin B (CTSB) (138), ECE-1, and ECE-2 (92, 96) preferentially degrade soluble monomeric or oligomeric AA (138) that is internalized within neurons and microglia.”
BackgroundInfluentialSelf-citationVan Nostrand, W. E., & Porter, M. (1999) · Biochemistry · doi:10.1021/bi990610f · Cited by 113 · cited 6×
“For example, intracellular enzymes such as IDE (112, 137), which is predominantly cytosolic, and the lysosomal-endosomal proteases cathepsin B (CTSB) (138), ECE-1, and ECE-2 (92, 96) preferentially degrade soluble monomeric or oligomeric AA (138) that is internalized within neurons and microglia.”
InfluentialMetabolism of amyloid β peptide and pathogenesis of Alzheimer's disease
Saido, T. C., & Iwata, N. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.12.015 · Cited by 112
Miners, J. S., Baig, S., Tayler, H., Kehoe, P. G., & Love, S. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181afe475 · Cited by 111 · cited 6×
“Interestingly, NEP and IDE levels decreased with age specifically within the AD cohort (26).”
BackgroundMethodInfluentialSelf-citationIkeda, K., Emoto, N., Raharjo, S. B., Nurhantari, Y., Saiki, K., Yokoyama, M., & Matsuo, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32469 · Cited by 108
Estrogen Stimulates Degradation of β-Amyloid Peptide by Up-regulating Neprilysin
Liang, K., Yang, L., Yin, C., Xiao, Z., Zhang, J., Liu, Y., & Huang, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.051664 · Cited by 108 · cited 1×
“Estrogen was reported to promote AA degradation of SH-SY-5Y human neuroblastoma cells by increasing NEP expression (241).”
BackgroundNovel activity of endothelin-converting enzyme: hydrolysis of bradykinin
HOANG, M. V., & TURNER, A. J. (1997) · Biochemical Journal · doi:10.1042/bj3270023 · Cited by 106
Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls
Sundelöf, J., Sundström, J., Hansson, O., Eriksdotter-Jönhagen, M., Giedraitis, V., Larsson, A., Degerman-Gunnarsson, M., Ingelsson, M., Minthon, L., Blennow, K., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101023 · Cited by 104 · cited 5×
“For example, intracellular enzymes such as IDE (112, 137), which is predominantly cytosolic, and the lysosomal-endosomal proteases cathepsin B (CTSB) (138), ECE-1, and ECE-2 (92, 96) preferentially degrade soluble monomeric or oligomeric AA (138) that is internalized within neurons and microglia.”
BackgroundInfluentialImage-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease
Lonser, R. R., Schiffman, R., Robison, A., Butman, J. A., Quezado, Z., Walker, M. L., Morrison, P. F., Walbridge, S., Murray, G. J., Park, D. M., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000247744.10990.e6 · Cited by 103
Kumar, U. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.04.001 · Cited by 101 · cited 6×
“The neuropeptide SST upregulates NEP activity in vitro (157) through activation of the SST receptors, SSTR2 and SSTR4, suggesting that AA levels might be controlled by SST receptor agonists (226).”
BackgroundInfluentialSomatostatin and Alzheimer's disease
Burgos‐Ramos, E., Hervás‐Aguilar, A., Aguado‐Llera, D., Puebla‐Jiménez, L., Hernández‐Pinto, A. M., Barrios, V., & Arilla, E. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.01.014 · Cited by 100 · cited 1×
“Reduction in SST (227) and SST receptor levels (228) may contribute to AA pathology in AD (229).”
BackgroundAkiyama, H., Kondo, H., Ikeda, K., Kato, M., & McGeer, P. L. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02390-3 · Cited by 99
Identification of renal cathepsin B as a human prorenin-processing enzyme
Wang, P. H., Do, Y. S., Macaulay, L., Shinagawa, T., Anderson, P. W., Baxter, J. D., & Hsueh, W. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98946-5 · Cited by 98 · cited 1×
“This suggests that AA-degrading proteases such as cathepsins B and D (219, 220) and ECE-2 (98), which work optimally within a mildly acidic pH of 5.”
BackgroundCerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease
Maruyama, M., Higuchi, M., Takaki, Y., Matsuba, Y., Tanji, H., Nemoto, M., Tomita, N., Matsui, T., Iwata, N., Mizukami, H., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20494 · Cited by 97 · cited 1×
“Disease progression was also associated with increased NEP level (172) and a trend toward increasing ACE level in human CSF (33).”
BackgroundHistone deacetylases: Focus on the nervous system
Morrison, B. E., Majdzadeh, N., & D’Mello, S. R. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7035-9 · Cited by 95 · cited 1×
“Several findings highlight the potential therapeutic use of valproate in AD (236): not only does it upregulate NEP, it also upregulates plasmin (237), and its safety and efficacy have been extensively documented in the treatment of epilepsy and psychosisYrelated behavioral problems (238).”
BackgroundLiao, M.-C., & Van Nostrand, W. E. (2010) · Biochemistry · doi:10.1021/bi901994d · Cited by 92 · cited 2×
“N, neprilysin (45Y49); E, endothelin-converting enzyme (49Y51); I, insulindegrading enzyme (47, 48, 52Y55); A, angiotensin-converting enzyme (56Y60); M2, matrix metalloproteinase 2 (61Y63); M9, matrix metalloproteinase 9 (64, 65); P, plasmin (28, 45, 51, 66, 67); C, CTSB (66); Mt1, membrane-type metalloproteinase 1 (6…”
BackgroundCathepsin D is involved in the clearance of Alzheimer's β‐amyloid protein
Hamazaki, H. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)01087-3 · Cited by 92
Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation
Carson, M. J., Sutcliffe, J. G., & Campbell, I. L. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990101)55:1<127::aid-jnr14>3.0.co;2-2 · Cited by 92
Gene therapy in Alzheimer’s disease – potential for disease modification
Nilsson, P., Iwata, N., Muramatsu, S., Tjernberg, L. O., Winblad, B., & Saido, T. C. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01038.x · Cited by 91 · cited 1×
“The potential of gene therapy for treatment of AD was the subject of an extensive recent review by Nilsson et al (245).”
BackgroundNeprilysin-2 Is an Important β-Amyloid Degrading Enzyme
Hafez, D. M., Huang, J. Y., Huynh, A. M., Valtierra, S., Rockenstein, E. M., Bruno, A. M., Lu, B., DesGroseillers, L., Masliah, E., & Marr, R. A. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.012 · Cited by 88 · cited 5×
“Mice with inactivation ofNEP (46), NEP-2 (145), ECE-1, ECE-2 (92), or IDE genes (114, 146) all showed a moderate (1.5- to 2-fold) increase in endogenous AA, thereby confirming that these enzymes contribute to the regulation of AA level in vivo.”
BackgroundInfluentialRestored degradation of the Alzheimer’s amyloid‐β peptide by targeting amyloid formation
Crouch, P. J., Tew, D. J., Du, T., Nguyen, D. N., Caragounis, A., Filiz, G., Blake, R. E., Trounce, I. A., Soon, C. P. W., Laughton, K., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05870.x · Cited by 88 · cited 1×
“Crouch et al (61) suggested that the accumulation of fibrillar AA may result from this decrease in susceptibility to proteolytic cleavage.”
BackgroundNeprylisin decreases uniformly in Alzheimer's disease and in normal aging
Russo, R., Borghi, R., Markesbery, W., Tabaton, M., & Piccini, A. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.09.054 · Cited by 87 · cited 1×
“However, in several studies, the correlation between the immunohistochemical assessment of NEP (usually involving limited numbers of subjects) and its measurement in brain tissue homogenates (usually by densitometry of Western blots) was poor (80, 164, 168).”
BackgroundMadani, R., Poirier, R., Wolfer, D. P., Welzl, H., Groscurth, P., Lipp, H., Lu, B., Mouedden, M. E., Mercken, M., Nitsch, R. M., et al. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21074 · Cited by 86 · cited 1×
“Inactivation of NEP in hAPP mice not only increased AA, including oligomeric AA (82), causing plaque-like deposits in the brain, but also impaired synaptic plasticity, caused behavioral and cognitive abnormalities (82, 151) and CAA (152).”
BackgroundYamada, T., Yoshiyama, Y., Sato, H., Seiki, M., Shinagawa, A., & Takahashi, M. (1995) · Acta Neuropathologica · doi:10.1007/bf00294800 · Cited by 85
Decreased Neprilysin Immunoreactivity in Alzheimer Disease, but Not in Pathological Aging
Wang, D.-S., Lipton, R. B., Katz, M. J., Davies, P., Buschke, H., Kuslansky, G., Verghese, J., Younkin, S. G., Eckman, C., & Dickson, D. W. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.5.378 · Cited by 85 · cited 1×
“Furthermore, the reduction in both NEP and IDE in AD was more pronounced in brain tissue from APOE ?4-positive patients (80, 106, 166, 167), whereas Hellstrom-Lindahl et al (168) reported decreased NEP protein (measured by immunoblot analysis) in AD and with age.”
BackgroundThe AβCs of Aβ-cleaving Proteases
Leissring, M. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800022200 · Cited by 84
Spencer, B., Marr, R. A., Rockenstein, E., Crews, L., Adame, A., Potkar, R., Patrick, C., Gage, F. H., Verma, I. M., & Masliah, E. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-109 · Cited by 84 · cited 5×
“Although it remains unproven that a decline in AAdegrading enzyme activity contributes to the accumulation of AA in AD (25, 26, 171), it is clear that overexpression of AA-degrading enzymes, neprilysin in particular, can reduce amyloid deposition and ameliorate cognitive decline in AD animal models (155, 161, 162).”
BackgroundInfluentialGDNF delivery for Parkinson’s disease
Patel, N. K., & Gill, S. S. (2007) · Springer eBooks · doi:10.1007/978-3-211-33081-4_16 · Cited by 84
Self-citationOverexpression of Insulin Degrading Enzyme: Cellular Localization and Effects on Insulin Signaling
Seta, K. A., & Roth, R. A. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6066 · Cited by 81
Research works printed but not linked: 3
- 10.1042/bst0331101 · doi:10.1042/bst0331101 · Paper page
- 10.1097/64.5.378 · doi:10.1097/64.5.378
- 10.1097/62.9.885 · doi:10.1097/62.9.885
Cited by
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Self-citationMicroglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota
Harach, T., Marungruang, N., Duthilleul, N., Cheatham, V., Mc Coy, K. D., Frisoni, G., Neher, J. J., Fåk, F., Jucker, M., Lasser, T., et al. (2017) · Scientific Reports · doi:10.1038/srep41802 · Cited by 901
Microglial dysfunction in brain aging and Alzheimer's disease
Mosher, K. I., & Wyss-Coray, T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.008 · Cited by 618
Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes
Katsuda, T., Tsuchiya, R., Kosaka, N., Yoshioka, Y., Takagaki, K., Oki, K., Takeshita, F., Sakai, Y., Kuroda, M., & Ochiya, T. (2013) · Scientific Reports · doi:10.1038/srep01197 · Cited by 565
Metadata
- Authors
- Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S.
- Affiliations
- Frenchay Hospital (GB)
- Corresponding author
- Miners, James Scott
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11
- Volume
- 70
- Issue
- 11
- Pages
- 944-959
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W1994344429
- Cited by
- 265
- References
- 287
- Citations by year
- 2026: 8 · 2025: 7 · 2024: 14 · 2023: 15 · 2022: 14 · 2021: 11 · 2020: 20 · 2019: 16 · 2018: 13 · 2017: 23 · 2016: 32 · 2015: 14 · 2014: 31 · 2013: 24 · 2012: 20
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Neuropathology & Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- Funders
- James Tudor Foundation
- Engineering and Physical Sciences Research Council (EP/G061866/1)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- amyloid-beta, Alzheimer's disease, neprilysin, insulin-degrading enzyme, endothelin-converting enzyme, cathepsin B, cerebral amyloid angiopathy, amyloid clearance, convection-enhanced delivery, gene therapy, cognitive impairment
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Glycopeptides, Humans, Insulysin, Mice, Transgenic, Protease Inhibitors, Thiorphan, Neprilysin, Genetic Therapy, Amyloid beta-Peptides, Microglia, Stem Cell Transplantation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.